
NASDAQHealthcareBiotechnology
Latest quote
$1.32
+$0.02 · +1.54%
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Previous close
$1.32
+$0.02 · +1.54%
Regular session · ET · Market data may be delayed.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Day range
Current $1.32
52-week range
Current $1.32
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
60
Mixed
Risk
38
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Day range
Current $1.32
52-week range
Current $1.32
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 260.5K USD | 123.44K USD | 3.1M USD |
| Cost of goods sold | — | 26.27K USD | 13.62M USD | 6.72K USD | 11.36M USD |
| Gross profit | — | −26.27K USD | −13.36M USD | 116.72K USD | −8.26M USD |
| Research and development | 29.79M USD | 17.21M USD | 13.62M USD | 12.03M USD | 11.36M USD |
| Selling, general, and administrative | 23.56M USD | 11.38M USD | 6.73M USD | 6.21M USD | — |
| Operating expenses | 51.97M USD | 28.56M USD | 6.73M USD | 18.25M USD | 6.51M USD |
| Interest income | 3.72M USD | 1.07M USD | 1.06M USD | 74.45K USD | 19.92K USD |
| Interest expense | — | — | — | 74.45K USD | 19.92K USD |
| Depreciation and amortization | 60.5K USD | 26.27K USD | 177.4K USD | 6.72K USD | 14.77M USD |
| Operating income | −51.97M USD | −28.59M USD | −20.09M USD | −18.13M USD | −14.77M USD |
| Net income | −48.26M USD | −27.52M USD | −19.03M USD | −18.05M USD | −14.79M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.83
265.91% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM4.7M0.01%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI4.6M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF1.82M0.00%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 Value ETFIWN1.71M0.01%13.05B USD0.24%$198.84-2.08%
Vanguard Russell 2000 ETFVTWO1.32M0.01%16.8B USD0.06%$103.76-2.76%
iShares Micro-Cap ETFIWC572.96K0.05%1.09B USD0.60%$157.87-3.19%
ALPS Medical Breakthroughs ETFSBIO223.78K0.13%170.88M USD0.50%$50.95-3.01%
Vanguard Russell 2000 Value ETFVTWV201.72K0.01%1.3B USD0.06%$175.33-2.02%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
ALPS Medical Breakthroughs ETFSBIO
Vanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.